HER2-positive Breast Cancer Video Perspectives

In a video interview, Ian E. Krop, MD, PhD, associate chief in the division of breast oncology at the Susan F. Smith Center for Women's Cancers and clinical research director at the Breast Oncology Center at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed:

• What’s new in the “quickly moving” HER2-positve breast cancer space, such as tyrosine kinase inhibitors (TKIs), antibody drug conjugates and more;
• Bispecific antibodies, checkpoint inhibitors and other therapies coming down the pipeline that hold promise for HER2-positive disease;
• How the emergence of new treatments for HER2-positive breast cancer may lead to the need to “personalize our treatment algorithms for individual patients” – “I don’t think we’re at a time anymore where we can use a one-size-fits-all approach;”
• Data from HER2CLIMB and DESTINY-Breast03 and their potential impact on clinical practice;
• The importance of the entire oncology community working to help ensure equitable care for patients;
• Addressing brain metastases in HER2-positive breast cancer as an important area of unmet need; and
• The “hope” that patients with metastatic breast cancer may be cured given the emergence of new, effective treatments.